Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001593506 | SCV001816536 | likely benign | not provided | 2020-09-18 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005023208 | SCV005663851 | uncertain significance | Rubinstein-Taybi syndrome due to EP300 haploinsufficiency; Colorectal cancer; Menke-Hennekam syndrome 2 | 2024-06-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV005330896 | SCV005994709 | uncertain significance | Inborn genetic diseases | 2025-02-20 | criteria provided, single submitter | clinical testing | The c.5926C>T (p.P1976S) alteration is located in exon 31 (coding exon 31) of the EP300 gene. This alteration results from a C to T substitution at nucleotide position 5926, causing the proline (P) at amino acid position 1976 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |